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Background: The aim of this study was to evaluate the incidence of local recurrence after SSM with IBR
and to determine whether complications lead to postponement of adjuvant therapy.
Method: Patients that underwent IBR after SSM between 2004 and 2011 were included.
Results: A total of 157 reconstruction procedureswere performed in 147 patients for invasive breast cancer
(n ¼ 117) and ductal carcinoma in situ (n ¼ 40). The median follow-up was 39 months [range 6e97].
Estimated 5-year local recurrence ratewas 2.9% (95%CI 0.1e5.7). Themedian time to start adjuvant therapy
was 27.5 days [range 19e92] in 18 patients with complications, and 23.5 days [range 8e54] in 46 patients
without complications (p ¼ 0.025).
Conclusion: In our single-institution cohort, IBR after SSM carried an acceptable local recurrence rate.
Complications caused a delay of adjuvant treatment but this was within guidelines and therefore not
clinically relevant.
 2013 Elsevier Ltd. All rights reserved.Background
The surgical treatment of breast cancer has changed dramati-
cally in the last decade. The extended radical mastectomy in the
19th century has evolved from standard mastectomy to breast
conserving surgery (BCS) in the 1980s [1]. During this period, skin-
sparing mastectomy (SSM) with immediate breast reconstruction
(IBR) was also introduced, which clearly improved the long-term
esthetic results [2]. IBR after SSM has gained popularity and has
been used in an increasing proportion of patients. In addition to the
gaining popularity, the number of patients with an indication foraastricht University Medical
rlands. Tel.: þ31 433877477;
sity.nl, tiaralp@gmail.com
All rights reserved.mastectomy is increasing due to improved pre-operative staging
with breast MRI [3] and the introduction of risk reducing surgery in
patients with hereditary breast cancer.
Breast reconstruction in combination with preservation of the
whole skin envelope compared to the standard mastectomy has
raised concerns about the oncological safety of the SSM in terms of
local recurrence. Breast tissue will always remain when sparing
skin [4]. In 2003, more than 60% of the breast surgeons reported to
avoid performing SSM because of the potential risk of local recur-
rence [5]. Besides local recurrence, another concern is that com-
plications of SSM with IBR might cause postponement of adjuvant
chemo- and radiotherapy. Several studies have shown that the
timing of receiving the ﬁrst course of adjuvant chemotherapy is
important for both avoiding local recurrence and improving overall
survival [6,7].
Therefore, the primary aim of this study is to evaluate the
incidence of local recurrence (or second primary) after SSM with
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complications due to SSM with IBR lead to postponement of
adjuvant chemotherapy or radiotherapy in patients with invasive
breast cancer.
Methods
Study population and data collection
Acquisition of informed consent was waived by a certiﬁed
medical ethics committee. All patients that underwent a SSM with
IBR for invasive breast cancer or carcinoma in situ in the period
2004e2011 were included. Patients who underwent prophylactic
mastectomy were excluded from the analyses. Data concerning
diagnosis, surgical procedures, histopathology, (neo-) adjuvant
therapy, and follow-up were retrospectively and starting January
2010, prospectively collected.
Multidisciplinary consultation
The possibility for SSMwith IBR was discussed preoperatively in
a multidisciplinary consultation, attended by a surgical oncologist,
medical oncologist, radiation oncologist, radiologist, and patholo-
gist. Eligible patients were referred to the plastic surgeon for
further consultation. High pre-operative risk for adjuvant radio-
therapy was a relative contra-indication. The choice of recon-
struction technique depended on several patient related factors
including breast size, ptosis, areola size, patient preference and
expectations, general health, smoking and timing of operation.
Postoperatively the deﬁnitive histopathology report and (indi-
cated) adjuvant therapy were multidisciplinary discussed.
Surgical procedure
A team of dedicated oncological and plastic surgeons performed
all surgical procedures. The nipple areola complex and breast pa-
renchyma were completely resected. Most of the SSM’s with autol-
ogous reconstructions were 1-stage operations. All reconstructions
witha tissueexpanderwere2-stageoperations; SSMwasperformed
in combination with placement of a tissue expander, which was
replaced by a deﬁnitive prosthesis in a second procedure.
Pathology
Biopsies and surgical specimens were ﬁxated in formalin.
Parafﬁn sections were cut and stained with hematoxylin and eosin
stain. The pathology report included tumor type, diameter, grade
(following Bloom and Richardson for invasive tumors and the
three-tier scheme for in situ tumors), lymphangio-invasion and
resection margins for both carcinoma in situ and invasive breast
cancer. Estrogen and progesterone status (immunohistochemistry)
and HER2 (with FISH technique) were determined in case of inva-
sive breast cancer. As part of the Dutch National Breast Cancer
Guidelines, hormone receptors are not determined in DCIS tumors.
Lymph node status was based on sentinel lymph node biopsy and/
or (complementary) axillary lymph node dissection.
Adjuvant therapy
Radiotherapy (RT), (neo-) adjuvant chemotherapy or adjuvant
hormonal treatment was indicated in accordance to Dutch guide-
lines [8]. The most common indication for neo-adjuvant chemo-
therapy was a large tumor in a relatively small breast. Radiotherapy
was indicated in case of “high risk” patients, to say, more than 3
positive lymph nodes, growth into the pectoral muscle, or tumorsize larger than 5 cm in combinationwith any of the following poor
prognostic characteristics: grade III tumor, lymphangio-invasion, or
age younger than 40 years. Furthermore, RT was indicated in pa-
tients with irradical resection margins. These patients were stan-
dardly treated with 50 gray and a boost of 16e26 gray.
Onset of adjuvant therapy
For the second aim of this study, only invasive breast cancer
patients who received chemo- or radiotherapy were included.
Complications that occurred in the post-operative period until the
day of the start of adjuvant treatment were registered. Time until
onset of adjuvant therapy was deﬁned as number of days between
date of the SSM and IBR and the start of the ﬁrst adjuvant therapy.
Complications were categorized in hematoma, wound infection,
seroma, and (partial) mastectomy skin ﬂap necrosis. Hematoma
was deﬁned as any collection of blood post-operative. Wound
infection was clinically diagnosed and treated with antibiotics.
Seroma was a clinical diagnosis of ﬂuid in the surgical cavity and
treated conservatively or with aspiration of the seroma. (Partial)
mastectomy skin ﬂap necrosis was deﬁned as necrosis of the skin
tissue isolated in the mastectomy skin ﬂap. Treatment was surgi-
cally with removal of the non-viable skin.
Follow-up and local recurrence
During the ﬁrst year after surgery, patients underwent physical
examination every three months. The second year patients were
examined twice a year, and afterward yearly. A contralateral
mammography was performed yearly in patients with unilateral
SSM and IBR. If the physical examination or imaging was suspicious
for malignancy, a histological biopsy and breast MRI were per-
formed. Recurrence was classiﬁed as local when located in the skin,
chest wall or subcutaneous tissue overlaying the reconstructed
breast. Regional lymph node metastases were classiﬁed as regional
recurrence. Screening for distant metastases was performed in case
of pathological proven local, regional recurrence or symptoms
associated with this.
Statistics
All collected data were analyzed with Statistical Package for the
Social Sciences (SPSS) version 19.0 (Chicago, Illinois, USA).
Descriptive statistics, student’s t-test, Fisher’s exact test, chi-square
test and ManneWhitney U test were used appropriately to
compare patients with and without complications. The Kaplane
Meier method was used to estimate the recurrence rate over time
in patients operated on for invasive and in situ carcinoma. A p-
value < 0.05 was considered statistically signiﬁcant.
Results
All patient and tumor characteristics are gathered in Table 1. The
median age of all included patients (n ¼ 147) was 51.8 years (SD
10.0). These patients underwent a total of 157 SSM with IBR. In-
dications for surgery were invasive breast cancer (n ¼ 117), ductal
carcinoma in situ (respectively n ¼ 40). Tissue expander (TE)
placement, deep inferior epigastric perforators (DIEP) ﬂap and
immediate implant were the most performed reconstructive pro-
cedures (Table 2).
Pathology
The mean tumor size was 19.7 mm (SD 16.6 mm) for invasive
breast cancer and 50.1 mm (SD 39.0 mm) for ductal carcinoma in
Table 2
Type of reconstructive breast procedures performed.
Reconstruction N (157)
Tissue expander placement 89
Deep inferior epigastric perforator ﬂap 42
Direct implant placement 21
Transverse rectus abdominis myocutaneous ﬂap 1
Lattissimus dorsi ﬂap 2
Transverse myocutaneous gracilis ﬂap 1
Superior gluteal artery perforator ﬂap 1
Table 4
Characteristics of the invasive carcinoma patients with and without complications
before start of adjuvant therapy.
Without
complications
(n ¼ 46)
With
complications
(n ¼ 18)
P-value
Age in years, mean (SD) 47.3 (9.8) 47.6 (11.1) 0.832
BMI, mean (SD) 23.5 (3.2) 24.1 (3.9) 0.549
Tumor size in mma, mean (SD) 25.3 (17.7) 28.6 (19.8) 0.516
Smoking, no (%) 8 (18) 3 (16) 0.905
Lymph node statusa, no (%)
N 25 (54) 10 (50) 0.745
Nþ 21 (46) 10 (50)
Neo-adjuvant therapy, no (%) 6 (13) 4 (22) 0.447
Post-operative complicationsa
TE loss, no (%) 4 (6)
Due to infection 2
Due to TE exposure 1
Due to irradical resection 1
Mastectomy ﬂap necrosis
(partial), no (%)
4 (6)
Infection, no (%) 2 (3)
Bleed, no (%) 5 (8)
Hematoma, no (%) 1 (2)
Seroma, no (%) 5 (8)
Free ﬂap problems, no (%) 1 (2)
Due to venous congestion 1
Abbreviations: BMI; body mass index, no; number, TE; Tissue expander.
a Calculated per breast (n ¼ 66).
Table 1
Patient and tumor characteristics.
DCIS (n ¼ 40) IBC (n ¼ 117)
Age in years, mean (SD) 55.1 (9.2) 51.0 (10.2)
Tumor size in mm, mean (SD)a 50.1 (39.0) 19.7 (16.6)
Tumor type, no (%)
Invasive ductal carcinoma 107 (91)
Invasive lobular carcinoma 10 (9)
Primary tumor, no (%)
pTis 40 (100) 0 (0)
pT1 0 62 (53)
pT2 0 35 (30)
pT3 0 6 (5)
Neo-adjuvant chemotherapy 0 14 (12)
Grade, no (%)
1 7 (17) 23 (20)
2 11 (28) 48 (41)
3 22 (55) 45 (38)
Unknown 0 (0) 1 (1)
Multi-, no (%)
Centric 4 (10) 9 (8)
Focal 12 (30) 50 (43)
Centric/focal 1 (3) 11 (9)
Unifocal 23 (57) 41
Unknown 0 6 (5)
Nodal status, no (%)
Negative 40 (100) 79 (67)
Positive 0 (0) 36 (31)
Unknown 0 2 (2)
Estrogen receptor status, no (%)
Positive NA 81 (70)
Negative NA 36 (30)
Progesterone receptor status, no (%)
Positive NA 77 (66)
Negative NA 40 (34)
HER2 receptor status, no (%)
Positive NA 28 (24)
Negative NA 84 (72)
Unknown NA 5 (4)
Abbreviations: DCIS; ductal carcinoma in situ, IBC; invasive breast cancer, NA; not
assessed, no; number.
a Calculated per breast (n ¼ 147).
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nodal status in invasive breast cancer was positive in 31% of the
breasts (n ¼ 36). In case of invasive breast cancer the estrogen
status was positive in 70% of the breasts (n ¼ 81). Of the breasts
with the pre-surgical indication of ductal carcinoma in situ, 9/47
had invasive breast cancer in deﬁnitive histopathology.Table 3
Characteristics of the four local recurrence cases.
Case Age Type Diameter Grade pN
1 48 IDC 13 mm 2 pN1mi
2 58 IDC 1.5 mm NA pN0
3 54 IDC 23 mm 2 pN0
4 54 DCIS 75 mm 2 pN0
Abbreviations: IDC; invasive ductal carcinoma, DCIS; ductal carcinoma in situ, ER; estr
receptor 2, Chtx; adjuvant chemotherapy, Rtx; adjuvant radiotherapy, Htx; adjuvant hoThirteen patients (14 breasts) received neo-adjuvant chemo-
therapy; of which ﬁve patients showed complete remission and
three patients had residual ductal carcinoma in situ only.Adjuvant therapy
Of all invasive breast cancer patients, 57/117 received adjuvant
chemotherapy (19 combined with trastuzumab), 14/117 neo-
adjuvant chemotherapy and 58/117 adjuvant hormonal therapy.
Radiotherapy was indicated in 23/117 patients for the following
indications: irradical resection margins (n ¼ 4), tumor size larger
than 3 cm (n ¼ 9) and more than 3 positive axillary lymph nodes
(n ¼ 10).Follow e up and recurrence
After a median follow-up of 39 months [range 6e97], local
recurrence occurred in 4 out of 157 breasts operated on for invasive
or in situ carcinoma (Table 3). Based on the patients only operated
on for invasive carcinoma, local recurrence occurred in 3/117 pa-
tients after a period of 16, 19 and 21 months. All primary tumors
were smaller than 3 cm, with resection margins larger than 1 mm.
One patient with DCIS of 7.5 cm and a radical resection margin of
0.50 mm had a local recurrence after 25 months. Only one patient
with local recurrence (after 21 months) developed synchronic
distant metastases.ER PR HER2 Chtx Rtx Htx
þ þ e No No No
e e e No No No
þ þ e No No Yes
NA NA NA No No No
ogen receptor, PR; progesterone receptor, HER2; human epidermal growth factor
rmone therapy, NA; not assessed.
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bined with chemotherapy and hormonal therapy for one patient,
excision and radiotherapy for the second patient, and hormonal
therapy for the last patient. The patient with synchronic metastases
was treated with radiotherapy and hormonal therapy for bone
metastases. A ﬁfth patient developed a regional (supra-clavicular)
recurrence after 31 months. Additional screening showed distant
metastases. This patient was treated with chemotherapy. Two pa-
tients developed distant metastases without local or regional
recurrence, both after 18months. Theywere treatedwith hormonal
therapy only. The KaplanMeier analysis to estimate the 5-year local
recurrence rate of the total population operated on for invasive and
in situ carcinoma, resulted in 2.9% (95% CI 0.1e5.7).
Postponement of systemic adjuvant therapy in patients with
complications
Only patients (n ¼ 64) receiving adjuvant chemo- and/or
radiotherapy for invasive carcinoma were included in this analysis.
Of these, two were treated for bilateral disease, resulting in a total
of 66 breasts. Patient and tumor characteristics and complications
are summarized in Table 4. In this sub-group of patients, compli-
cations occurred in 20/66 breasts, namely: mastectomy (partial)
ﬂap necrosis (n ¼ 4), anastomosis revision due to venous conges-
tion of ﬂap (n ¼ 1), TE-loss (n ¼ 4), post-operative bleed (n ¼ 5),
wound infections (n ¼ 2), hematoma (n ¼ 1), and seroma (n ¼ 5).
There were no cases of ﬂap loss. One patient with bilateral disease
had more than one complication in both breasts. There were no
signiﬁcant differences in patient- and tumor characteristics
considering the patients with or without complications (Table 4).
The median time between the SSM with IBR and the start of
adjuvant chemo- or radiotherapy was 27.5 days [range 19e92] in
the group with complications, compared with 23.5 days [range 8e
54] in the group without complications (p ¼ 0.025). Moreover, 85%
(56/64) of the patients receiving adjuvant therapywere able to start
their treatment within 6 weeks postoperatively. The majority of the
patients, 94% (60/64), started adjuvant treatment within 7 weeks.
Discussion
This study concerns the oncological safety of SSM followed by
IBR in terms of local recurrence rate and delay of adjuvant therapy.
A 5-year local recurrence rate of 2.9% was estimated after IBR and
SSM in our cohort of 157 women. This is in line with the current
literature. A meta-analysis of nine studies with 918 patients un-
dergoing a SSM versus 2518 patients undergoing a standard mas-
tectomy reported no signiﬁcant difference in local recurrence
between the SSM versus standard mastectomy groups (6.2% vs.
4.0%) [9]. Recently a cohort of 207 women after SSM followed by
IBRwith amedian follow-up of 10 years was published with a local-
recurrence rate of 11.1% [10].
Generally, most studies have limitations concerning the het-
erogeneous population with a wide variety of high-, medium- and
low-risk patients. However, a prospective randomized controlled
trial comparing SSM versus standard mastectomy in terms of local
recurrence rate and overall survival will probably never be
accomplished. Therefore, registration studies remain the second
best option for acquiring evidence.
3The strength of our study, as compared to other published data,
is a detailed registration of indication for operation, pre-operative
work-up, surgical and pathological results and indications of
(neo-) adjuvant therapy.
In addition, there are important inconsistencies in the compo-
sition of endpoints deﬁnitions in breast cancer trials, particularly
those consisting of multiple components [11]. For example theendpoints: local-, regional- and locoregional recurrence rates.
Some studies do not differentiate between local and regional
recurrence, instead they report a cumulative locoregional recur-
rence rate. With respect to the oncological safety of SSM followed
by IBR, it is essential to only compare local recurrence rates in SSM
studies with the rates in standard mastectomy studies. As for dif-
ferences in endpoint deﬁnitions, an example can bemade of a study
by Romics Jr. et al. [10]. They reported a local recurrence rate of 2.9%
and a locoregional rate of 8.2%. However, the true local recurrence
rate was 11.1%. Patients with a synchronous local and regional
recurrence were only counted as having a locoregional recurrence.
Thus they were not included in the reported rate of the local
recurrence, resulting in a lowered true local recurrence rate.
The theoretical increase of recurrence rates is due to the residual
breast tissue underlying the skin ﬂap. The skin surplus in SSM’s
compared to standard mastectomy contains residual breast tissue
in almost 60% of the surgeries [12]. When looking at the mean
weighted amount of residual breast tissue, this was reported to be a
mere 0.02% of the total removed breast tissue [13]. With all of this
in mind, we must ask ourselves if the residual breast tissue in SSM
is indeed a well-founded concern [4].
In this study a signiﬁcant difference was detected in the length
of the period from breast surgery to onset of adjuvant therapy
between the group with and without complications. This is in line
with other reports [14] but also in contradiction to others [15e17].
An important difference with the contradicting studies is that most
of them focus on the effect of IBR on the length of the period from
SSMwith IBR to adjuvant therapy compared to patients undergoing
mastectomy only. The current study compares the period from
operation to start of adjuvant therapy for patients with andwithout
complications after SSM with IBR. The start of adjuvant chemo-
therapy according to current guidelines should be within 5e12
weeks. Further delay of adjuvant treatment could have adverse
effects on systemic recurrence and survival [7,18,19]. With a re-
portedmedian onset of adjuvant therapy of 27.5 days in our patient
group with complications, it is within the established guidelines
and therefore not clinically relevant.
Themain limitations of the current study are the relatively short
follow-up and the lack of a case-matched mastectomy group. Based
on literature, most disease recurrences occur within the ﬁrst 2e3
years after primary treatment [20]. Our cohort had a median
follow-up period of 39 months, thus most patients had already
passed the time frame of disease recurrence. Not withstanding
these limitations, (almost) all studies including this study (2.9%)
show acceptable local recurrence rates. Moreover, local recurrences
occurred after a period of 16e25 months, which is well within the
median follow up period. Other studies report local recurrences
after a comparable period of 14e27 months [21,22].
Conclusion
In conclusion, SSM with IBR is a safe procedure with an
acceptable local recurrence rate. Complications due to SSM with
IBR caused a signiﬁcant delay of adjuvant treatment but the clinical
consequences of this delay are not fully investigated. Based on the
outcome of this study in combination with the available literature,
performing a SSM followed by IBR improves patient satisfaction
while having no negative affect on the oncological outcome.
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